Drug Profile
Interleukin-15
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Amgen
- Class Adjuvants; Immunotherapies; Interleukins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chemotherapy-induced damage; HIV-1 infections; Muscular atrophy; Radiation injuries
Most Recent Events
- 24 Jul 2002 Immunex has been acquired by, and merged into, Amgen
- 17 Oct 2000 A preclinical study has been added to the Cancer pharmacodynamics section
- 17 Jul 2000 Preclinical development for Chemotherapy induced damage (Prevention)/Chemoprotection and Radiation injuries (Prevention)/Radioprotection in USA (Unknown route)